Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Down 39.1% in February

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 520,300 shares, a decrease of 39.1% from the January 31st total of 853,700 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.4% of the shares of the stock are short sold.

Institutional Trading of Inspira Technologies Oxy B.H.N.

A hedge fund recently raised its stake in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC lifted its position in shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 142.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,622 shares of the company’s stock after acquiring an additional 21,532 shares during the quarter. Renaissance Technologies LLC owned 0.29% of Inspira Technologies Oxy B.H.N. worth $37,000 at the end of the most recent quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

Inspira Technologies Oxy B.H.N. Stock Performance

Shares of NASDAQ IINN traded down $0.03 during trading on Monday, hitting $0.87. 170,031 shares of the company were exchanged, compared to its average volume of 1,681,875. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.23 and a quick ratio of 2.13. Inspira Technologies Oxy B.H.N. has a 1 year low of $0.77 and a 1 year high of $2.45. The firm’s fifty day moving average price is $0.97 and its 200 day moving average price is $1.15.

Inspira Technologies Oxy B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.